Articles from VectorBuilder

VectorBuilder, a global leader in gene delivery technologies and CDMO services, and MaxCyte, a leading, cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced a strategic partnership focused on co-developing a new gene delivery solution using VectorBuilder’s proprietary MiniVec™ plasmid system and MaxCyte’s world-class clinical electroporation platform for ex vivo cell engineering.

VectorBuilder, a global leader in gene delivery technologies, today announced plans to invest $50 million to establish a new Advanced Biomanufacturing and R&D Center in Chicago, marking a major expansion of the company’s regional operations and long-term commitment to supporting the development of genetic medicines.

VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, will participate in the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 11 to 15 in Boston, Massachusetts.

VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced that its MiniVec™ plasmid system has been granted a European patent, marking a significant milestone for the company’s proprietary plasmid DNA technology and reinforcing its position at the forefront of gene delivery innovation.

VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, will participate in the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in Denver, Colorado, from May 3 to 7.

VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a high-stability AAV vector designed to address ITR instability, a common challenge in gene therapy development. The manuscript describing the technology is now available on bioRxiv.

VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered for safer, more efficient, and more scalable development of genetic medicines. The manuscript detailing this breakthrough is now available on BioRxiv.

VectorBuilder, a global leader in the gene delivery space, has won two prestigious awards at the Asia-Pacific Cell and Gene Therapy Excellence Awards 2025 (APCGTEA) and the Asia-Pacific Biologics CDMO Excellence Awards 2025 (APBCEA), hosted by IMAPAC.

VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) on January 11, 2025. VectorBuilder has provided highly customized end-to-end CDMO solutions to support this clinical pipeline.

VectorBuilder, a global leader in gene delivery solutions, is excited to announce that it’s received the BioIndustrial Innovation of the Year award by the BioTech Breakthrough Awards. The recognition underscores VectorBuilder’s significant contributions to gene delivery technology through its Vector Design Studio, which has revolutionized the way researchers worldwide create and order custom gene delivery vectors.

VectorBuilder, a global leader in gene delivery solutions, announced today that its Chief Scientist, Dr. Bruce Lahn, has been honored as a PharmaVoice 100 winner. This prestigious annual list recognizes the most inspiring and influential leaders in the life sciences industry.